Filtered By:
Condition: Ischemic Stroke
Procedure: Heart Transplant
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 279 results found since Jan 2013.
Sustained Use of the Impella 5.0 Heart Pump Enables Bridge to Clinical Decisions in 34 Patients
Tex Heart Inst J. 2021 Jul 1;48(3):e207260. doi: 10.14503/THIJ-20-7260.ABSTRACTWe studied whether sustained hemodynamic support (>7 d) with the Impella 5.0 heart pump can be used as a bridge to clinical decisions in patients who present with cardiogenic shock, and whether such support can improve their outcomes. We retrospectively reviewed cases of patients who had Impella 5.0 support at our hospital from August 2017 through May 2019. Thirty-four patients (23 with cardiogenic shock and 11 with severely decompensated heart failure) underwent sustained support for a mean duration of 11.7 ± 9.3 days (range, ≤48 d). Of 2...
Source: Texas Heart Institute Journal - August 13, 2021 Category: Cardiology Authors: Daniel W Nelson Sakthi Sundararajan Evan Klein Lyle D Joyce Lucian A Durham David L Joyce Asim A Mohammed Source Type: research
Risk factors for heart transplant survival with greater than 5 h of donor heart ischemic time
ConclusionPreservation time >5 h is associated with worse survival. This mortality risk is further amplified by preoperative dialysis and ECMO, ischemic cardiomyopathy etiology, and use of O blood type donor hearts.
Source: Journal of Cardiac Surgery - May 21, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Paul C. Tang,
Ienglam Lei,
Y. E. Chen,
Zhong Wang,
Gorav Ailawadi,
Matthew A. Romano,
Shachi Salvi,
Keith D. Aaronson,
Ming ‐Sing Si,
Francis D. Pagani,
Jonathan W. Haft Tags: ORIGINAL ARTICLE Source Type: research
Late-Breaking Data at ACC.21 Show XARELTO ® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization
RARITAN, N.J., May 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO® plus aspirin reduced first events by 15 percent among patients with PAD ...
Source: Johnson and Johnson - May 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Neurologic Complications After Pediatric Heart Transplant: A Single-Center Experience
CONCLUSIONS: Neurologic complications may lead to serious mortality and morbidity in pediatric heart transplant patients. Seizures, posterior reversible encephalopathy syndrome, stroke, peripheral neuropathy, transient ischemic attack, and cerebral infections are the most common neurologic complications, which are seen in the perioperative period in particular. Careful follow-up of pediatric heart transplant patients, with detection and early treatment of neurologic findings, will contribute to lower rates of sequelae. To our knowledge, this is the largest study to show a detailed experience of neurologic complications in ...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - April 2, 2021 Category: Transplant Surgery Authors: Ali Orgun Ilkay Erdogan Birg ül Varan Taner Sezer N K ürsad Tokel Murat Özkan Atilla Sezgin Source Type: research
